Investigating the Prognosis of Pulmonary Patients Based On the NLR Index
Authors
-
Hamid Reza Mehryar
- Department of Emergency Medicine, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
https://orcid.org/0000-0002-3267-8647
-
Zahra Mosavinejad
- Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
https://orcid.org/0000-0002-4022-7811
-
Masoumeh Rabie Pour*
- Department of Internal Medicine, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
https://orcid.org/0000-0002-7088-3684
DOI:
https://doi.org/10.22100/jkh.v20i4.3206Keywords:
Covid-19 , Neutrophil, LymphocyteAbstract
Introduction: The neutrophil-to-lymphocyte ratio (NLR), derived from complete blood count differentials, serves as a marker of systemic inflammation. Given that neutrophil counts normally increase and lymphocyte counts may decrease with the progression of inflammatory disease, this study investigates the prognostic utility of the NLR in pulmonary patients.
Methods: This was a descriptive-analytical, cross-sectional study carried out between January and June 2021. Data were collected from 2500 COVID-19 patients admitted to Imam Khomeini Hospital in Urmia using a census sampling method. The demographic information checklist was used to collect the data.
Results: The results exhibited that out of 2500 participants, the majority were female (54.1%; 1353), the age group between 50-59 years (22.2%; 556) was most represented, and 85.2% (2129) had been discharged from the hospital. The average WBC in the studied patients was 10056.51±8268.11, and the average neutrophil-to-lymphocyte ratio was 8.2±7.2. The mean hospitalization period was 5.9±7.5 days. Moreover, a significant relationship was found between disease outcome, hospitalization department, age, and length of hospitalization with the neutrophil-to-lymphocyte ratio.
Conclusion: According to our results, with an increase in the NLR ratio, the death rate of patients with covid-19 as well as the rate of hospitalization in ICU increases, and this ratio is higher in older patients.
References
Christensen B, Favaloro EJ, Lippi G, Van Cott EM. Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19). Semin Thromb Hemost 2020t;46:845-9. doi: 10.1055/s-0040-1715458
Huang Z, Fu Z, Huang W, Huang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. The American Journal of Emergency Medicine 2020;38:641-7. doi: 10.1016/j.ajem.2019.10.023
Tatum D, Taghavi S, Houghton A, Stover J, Toraih E, Duchesne J. Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients. Shock 2020;54:652-8. doi: 10.1097/SHK.0000000000001585
Kerboua KE. NLR: a cost-effective nomogram to guide therapeutic interventions in COVID-19. Immunological Investigations 2021;50:92-100. doi: 10.1080/08820139.2020.1773850
Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection 2020;81:e6-e12. doi: 10.1016/j.jinf.2020.04.002
Islamoglu MS, Borku-Uysal B, Yavuzer S, Ikitimur H, Seyhan S, Koc S, Cengiz M. The Diagnostic and Predictive Roles of Neutrophil-Lymphocyte Ratio for Severity of Disease in COVID-19 Patients. Clin Lab 2021;67. doi: 10.7754/Clin.Lab.2021.210449.
Soytaş RB, Ünal D, Arman P, Suzan V, Gedik TE, Can G, et al. Factors affecting mortality in geriatric patients hospitalized with COVID-19. Turkish Journal of Medical Sciences 2021;51:454-63. doi: 10.3906/sag-2008-91
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases 2020;71:762-8. doi: 10.1093/cid/ciaa248
Nalbant A, Demirci T, Kaya T, Aydın A, Altındiş M, Güçlü E. Can prognostic nutritional index and systemic immune‐inflammatory index predict disease severity in COVID‐19? International Journal of Clinical Practice 2021;10:e14544. doi: 10.1111/ijcp.14544
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology 2020;146:110-8. doi: 10.1016/j.jaci.2020.04.006
Jimeno S, Ventura PS, Castellano JM, García‐Adasme SI, Miranda M, Touza P, et al. Prognostic implications of neutrophil‐lymphocyte ratio in COVID‐19. European Journal of Clinical Investigation 2021;51:e13404. doi: 10.1111/eci.13404
Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S, Pisano M, et al. Neutrophil‐to‐lymphocyte ratio: an emerging marker predicting prognosis in elderly adults with community‐acquired pneumonia. Journal of the American Geriatrics Society 2017;65:1796-801. doi: 10.1111/jgs.14894
Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory coronavirus disease 2019 in Wuhan, China. Clinical Infectious Diseases 2021;73:e4208-e13. doi: 10.1093/cid/ciaa270
Kaya T, Yaylacı S, Nalbant A, Yıldırım İ, Kocayiğit H, Çokluk E, Şekeroğlu MR, Köroğlu M, Güçlü E. Serum calprotectin as a novel biomarker for severity of COVID-19 disease. Ir J Med Sci 2022;191:59-64. doi: 10.1007/s11845-021-02565-8
Ciccullo A, Borghetti A, Dal Verme LZ, Tosoni A, Lombardi F, Garcovich M, et al. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. International Journal of Antimicrobial Agents 2020;56:106017-28. doi: 10.1016/j.ijantimicag.2020.106017
Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine 2020;58:1021-8. doi: 10.1515/cclm-2020-0369
Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. European Journal of Medical Research 2020;25:1-10. doi: 10.1186/s40001-020-00432-3
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
